Literature DB >> 9224214

Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40, and CD30L.

L P Nicod1, P Isler.   

Abstract

Alveolar macrophages (AM) from sarcoid patients have been shown to be good antigen presenting cells (APC) unlike normal AM which are usually ineffective. We demonstrate in ten consecutive sarcoid patients that most of their AM, unlike normal AM, do coexpress high levels of CD86, CD40, and CD30L, all known to be important for T-cell activation. CD80 is also slightly more expressed on sarcoid AM than on normal AM, but is detected on only 26 +/- 6% (mean +/- SEM) of sarcoid AM. A good correlation is present between the percentage of sarcoid AM expressing CD86 and CD40 or CD86 and CD30L. However, no correlation is found between the percentage of CD80 and CD86 positive AM in these same patients. Blocking antibodies against CD86 were able to reduce by more than 80% allogeneic T-cell proliferation induced by the AM of sarcoid patients. This study provides evidence that AM can, in pathologic states such as sarcoidosis, express functional costimulatory molecules for T-cell activation such as CD86, thought to be rather specific for more professional APC such as dendritic cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224214     DOI: 10.1165/ajrcmb.17.1.2781

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  14 in total

1.  Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.

Authors:  J Wahlström; M Berlin; C M Sköld; H Wigzell; A Eklund; J Grunewald
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 2.  Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.

Authors:  S E Burastero; G A Rossi
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

3.  In situ expression of B7 and CD40 costimulatory molecules by normal human lung macrophages and epithelioid cells in tuberculoid granulomas.

Authors:  P Soler; V Boussaud; J Moreau; A Bergeron; P Bonnette; A J Hance; A Tazi
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Bone marrow-derived cells are required for the induction of a pulmonary inflammatory response mediated by CD40 ligation.

Authors:  J A Wiley; A G Harmsen
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

5.  A subset of human uterine endometrial macrophages is alternatively activated.

Authors:  Amy L Jensen; Jane Collins; Emilie P Shipman; Charles R Wira; Paul M Guyre; Patricia A Pioli
Journal:  Am J Reprod Immunol       Date:  2012-08-06       Impact factor: 3.886

Review 6.  Dendritic cells in the pathogenesis of sarcoidosis.

Authors:  Lisa C Zaba; Gideon P Smith; Miguel Sanchez; Stephen D Prystowsky
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

7.  Evidence for local dendritic cell activation in pulmonary sarcoidosis.

Authors:  Bregje Ten Berge; Alex Kleinjan; Femke Muskens; Hamida Hammad; Henk C Hoogsteden; Rudi W Hendriks; Bart N Lambrecht; Bernt Van den Blink
Journal:  Respir Res       Date:  2012-04-18

8.  Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.

Authors:  Alessandro Barbieri; Marzia Dolcino; Elisa Tinazzi; Antonella Rigo; Giuseppe Argentino; Giuseppe Patuzzo; Andrea Ottria; Ruggero Beri; Antonio Puccetti; Claudio Lunardi
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

Review 9.  Alveolar macrophages: plasticity in a tissue-specific context.

Authors:  Tracy Hussell; Thomas J Bell
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

10.  A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.

Authors:  Xiuqi Liang; Lu Li; Xinchao Li; Tao He; Songlin Gong; Shunyao Zhu; Miaomiao Zhang; Qinjie Wu; Changyang Gong
Journal:  Theranostics       Date:  2021-05-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.